Jefferies Financial Group Inc. Buys 150,755 Shares of Doximity, Inc. $DOCS

Jefferies Financial Group Inc. grew its stake in shares of Doximity, Inc. (NYSE:DOCS – Free Report) by 526.3% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 179,400 shares of the company’s stock after acquiring an additional 150,755 shares during the period. Jefferies Financial Group Inc.’s holdings in Doximity were worth $5,084,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Riverbridge Partners LLC boosted its position in Doximity by 7.9% during the 3rd quarter. Riverbridge Partners LLC now owns 303,539 shares of the company’s stock valued at $8,602,000 after acquiring an additional 22,320 shares in the last quarter. Lido Advisors LLC purchased a new stake in shares of Doximity during the 3rd quarter valued at $281,000. M&G PLC lifted its holdings in shares of Doximity by 96.4% during the 3rd quarter. M&G PLC now owns 577,196 shares of the company’s stock valued at $16,161,000 after purchasing an additional 283,296 shares during the last quarter. Fulcrum Asset Management LLP lifted its holdings in shares of Doximity by 17,401.8% during the 3rd quarter. Fulcrum Asset Management LLP now owns 66,857 shares of the company’s stock valued at $1,773,000 after purchasing an additional 66,475 shares during the last quarter. Finally, Brighton Jones LLC acquired a new stake in Doximity in the third quarter worth about $239,000. 87.19% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, CAO Siddharth Sitaram sold 2,613 shares of the stock in a transaction on Wednesday, October 14th. The stock was sold at an average price of $30.68, for a total transaction of $80,166.84. Following the completion of the transaction, the chief accounting officer directly owned 101,432 shares in the company, valued at approximately $3,111,933.76. This represents a 2.51% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Timothy Cabral sold 10,721 shares of the stock in a transaction dated Thursday, November 5th. The stock was sold at an average price of $35.00, for a total transaction of $375,235.00. Following the transaction, the director directly owned 8,084 shares of the company’s stock, valued at approximately $282,940. This trade represents a 57.01% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 22,701 shares of company stock valued at $717,401. 31.80% of the stock is owned by company insiders.

Doximity News Summary

These are some of the DOCS news items that stood out recently:

  • Positive Sentiment: Doximity reportedly rolled out DoseCheck, a medication-dosing tool, following a period of near-zero drug-dosing errors. The product could support its offerings for healthcare professionals, though the article provides limited detail on its commercial impact. Doximity rolls out DoseCheck
  • Neutral Sentiment: Barclays raised its DOCS price target to $30 from $27 while maintaining an “equal weight” rating. The higher target is a modest positive revision, but remains below the $33.28 share price cited in the provided background. Barclays sets a new price target
  • Negative Sentiment: Several law firms publicized a securities class action covering investors who bought DOCS shares from August 8, 2024, through May 13, 2026, with a November 16 deadline to seek lead-plaintiff status. The complaint alleges Doximity misled investors about engagement, competitive share and revenue expectations, including allegedly lowering and then missing fiscal 2026 guidance. The repeated announcements may renew concern about legal and reputational risk; the allegations remain unproven. Class action deadline and allegations

Doximity Stock Up 0.2%

Shares of NYSE:DOCS opened at $33.28 on Friday. Doximity, Inc. has a 52-week low of $17.15 and a 52-week high of $51.85. The business has a fifty day moving average of $29.61 and a two-hundred day moving average of $25.36. The stock has a market cap of $5.93 billion, a P/E ratio of 46.22, a PEG ratio of 34.61 and a beta of 1.29.

Doximity (NYSE:DOCS – Get Free Report) last released its quarterly earnings data on Thursday, November 5th. The company reported $0.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.19 by $0.17. The firm had revenue of $174.54 million during the quarter. Doximity had a net margin of 21.12% and a return on equity of 15.80%. Doximity’s revenue for the quarter was up 3.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.45 earnings per share. On average, equities analysts anticipate that Doximity, Inc. will post 0.74 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the stock. Wells Fargo & Company downgraded shares of Doximity from an “equal weight” rating to an “underweight” rating and set a $18.00 price objective for the company. in a research note on Monday, August 10th. Canaccord Genuity Group raised their price objective on shares of Doximity from $36.00 to $40.00 and gave the stock a “buy” rating in a research note on Friday, November 6th. Barclays upped their price target on Doximity from $27.00 to $30.00 and gave the stock an “equal weight” rating in a report on Wednesday. Freedom Capital cut Doximity from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 8th. Finally, Wolfe Research raised shares of Doximity to an “outperform” rating in a report on Thursday, August 13th. Eight research analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat.com, Doximity presently has a consensus rating of “Hold” and a consensus target price of $30.59.

Read Our Latest Analysis on Doximity

About Doximity

(Free Report)

Doximity, Inc. operates a digital platform designed for medical professionals, including physicians and other clinicians. Its services support professional networking, medical news and research discovery, career development, and communication among healthcare professionals. The company also offers clinical workflow tools, including Doximity Dialer, which enables clinicians to make calls and conduct video visits using a work number, as well as digital fax and document services. Doximity provides marketing and recruitment solutions to healthcare organizations and life sciences companies.

Read More

Want to see what other hedge funds are holding DOCS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Doximity, Inc. (NYSE:DOCS – Free Report).

Institutional Ownership by Quarter for Doximity (NYSE:DOCS)

Receive News & Ratings for Doximity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Doximity and related companies with MarketBeat.com's FREE daily email newsletter.